# Efficacy and Safety of SHR-2010 Injection in the Treatment of Primary IgA Nephropathy

> **NCT05847920** · PHASE2 · TERMINATED · sponsor: **Guangdong Hengrui Pharmaceutical Co., Ltd** · enrollment: 53 (actual)

## Conditions studied

- Primary IgA Nephropathy

## Interventions

- **DRUG:** SHR-2010 Injection
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05847920
- **Lead sponsor:** Guangdong Hengrui Pharmaceutical Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-06-04
- **Primary completion:** 2025-01-20
- **Final completion:** 2025-01-20
- **Target enrollment:** 53 (ACTUAL)
- **Why stopped:** Based on the adjustment of the R \& D strategy, the sponsor decides to terminate the research.
- **Last updated:** 2025-03-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05847920

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05847920, "Efficacy and Safety of SHR-2010 Injection in the Treatment of Primary IgA Nephropathy". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT05847920. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*